Ancora Advisors LLC Makes New $3 Million Investment in Medtronic PLC $MDT

Ancora Advisors LLC bought a new position in Medtronic PLC (NYSE:MDT - Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 38,416 shares of the medical technology company's stock, valued at approximately $3,005,000.

Other institutional investors also recently modified their holdings of the company. New England Capital Financial Advisors LLC raised its holdings in shares of Medtronic by 7.8% in the 4th quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company's stock valued at $135,000 after acquiring an additional 101 shares in the last quarter. Ipsen Advisor Group LLC grew its holdings in shares of Medtronic by 1.7% during the fourth quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company's stock worth $572,000 after purchasing an additional 101 shares in the last quarter. Quadrant Capital Group LLC grew its holdings in shares of Medtronic by 0.3% during the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company's stock worth $3,120,000 after purchasing an additional 101 shares in the last quarter. Rossby Financial LCC increased its position in shares of Medtronic by 5.1% in the fourth quarter. Rossby Financial LCC now owns 2,193 shares of the medical technology company's stock worth $211,000 after purchasing an additional 107 shares during the last quarter. Finally, Wealthspire Retirement LLC increased its position in shares of Medtronic by 5.0% in the fourth quarter. Wealthspire Retirement LLC now owns 2,410 shares of the medical technology company's stock worth $232,000 after purchasing an additional 114 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s rebound is being supported by expectations for continued momentum in its Cardiovascular, Neuroscience and Diabetes businesses. Investors will look to the upcoming fiscal Q1 report for evidence that recent growth trends are sustainable. Can Medtronic continue its rebound? We’ll get more answers soon
• Positive Sentiment: The board approved a fiscal 2027 second-quarter cash dividend of $0.72 per share, reaffirming Medtronic’s dividend-growth path and supporting the stock’s appeal to income-focused investors. Medtronic Affirms Dividend Path
• Positive Sentiment: Analysts describe Medtronic as a diversified and comparatively lower-priced alternative to Intuitive Surgical in surgical robotics, potentially attracting investors seeking medical-device exposure at a less demanding valuation. ISRG vs. MDT: Which Surgical Robot Stock Is the Smarter Buy?
• Neutral Sentiment: The upcoming earnings release is the main near-term catalyst. Forecasts point to potential growth across key businesses, but available earnings-beat signals are mixed, leaving investors focused on revenue, margins and management guidance. MDT’s Q1 Earnings on Deck
• Neutral Sentiment: A global medication-adherence market report lists Medtronic among companies positioned to benefit from connected devices, AI-enabled platforms, telehealth and home-care integration, although it does not announce a specific new contract or financial impact for MDT. Medication Adherence Global Market Report 2026-2035
• Negative Sentiment: After a strong short-term recovery, some commentary questions whether Medtronic is now fully valued, increasing the risk of profit-taking if upcoming results or guidance fail to exceed expectations. Medtronic Affirms Dividend Path, Is the Stock Fully Valued?

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the business's stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the sale, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.27% of the company's stock.

Medtronic Price Performance

Shares of Medtronic stock opened at $92.16 on Thursday. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33. The stock has a market capitalization of $117.96 billion, a price-to-earnings ratio of 24.71, a price-to-earnings-growth ratio of 2.44 and a beta of 0.55. The company has a fifty day moving average of $85.12 and a 200-day moving average of $85.72. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13.

Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The firm had revenue of $9.81 billion for the quarter, compared to analysts' expectations of $9.62 billion. During the same period last year, the firm earned $1.62 earnings per share. The company's revenue for the quarter was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities research analysts expect that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic's payout ratio is 77.21%.

Analyst Ratings Changes

Several analysts have recently weighed in on MDT shares. Piper Sandler restated a "neutral" rating on shares of Medtronic in a research report on Monday, August 10th. Leerink Partners cut their target price on shares of Medtronic from $117.00 to $104.00 and set an "outperform" rating for the company in a research report on Thursday, June 4th. Wall Street Zen upgraded shares of Medtronic from a "hold" rating to a "buy" rating in a research report on Saturday, July 18th. Jefferies Financial Group reissued a "hold" rating and issued a $88.00 target price on shares of Medtronic in a research note on Thursday, June 4th. Finally, TD Cowen lowered their price target on Medtronic from $119.00 to $100.00 and set a "buy" rating on the stock in a research report on Friday, July 10th. Eighteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Medtronic has an average rating of "Moderate Buy" and an average target price of $98.83.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source